These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35543250)

  • 1. Inside the cracked kernel: establishing the molecular basis of AMG510 and MRTX849 in destabilising KRASG12C mutant switch I and II in cancer treatment.
    Issahaku AR; Salifu EY; Soliman MES
    J Biomol Struct Dyn; 2023 Jul; 41(11):4890-4902. PubMed ID: 35543250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRAS
    Issahaku AR; Mukelabai N; Agoni C; Rudrapal M; Aldosari SM; Almalki SG; Khan J
    Sci Rep; 2022 Oct; 12(1):17796. PubMed ID: 36273239
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Tu G; Liu Q; Qiu Y; Leung EL; Yao X
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.
    Pandey D; Chauhan SC; Kashyap VK; Roy KK
    Eur J Med Chem; 2024 Nov; 277():116771. PubMed ID: 39167893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.
    Kirschner T; Müller MP; Rauh D
    J Med Chem; 2024 Apr; 67(8):6044-6051. PubMed ID: 38621359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A saturation mutagenesis screen uncovers resistant and sensitizing secondary
    Feng S; Callow MG; Fortin JP; Khan Z; Bray D; Costa M; Shi Z; Wang W; Evangelista M
    Proc Natl Acad Sci U S A; 2022 May; 119(18):e2120512119. PubMed ID: 35471904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS mutation: from undruggable to druggable in cancer.
    Huang L; Guo Z; Wang F; Fu L
    Signal Transduct Target Ther; 2021 Nov; 6(1):386. PubMed ID: 34776511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of the GTPase KRAS
    Xu Q; Zhang G; Liu Q; Li S; Zhang Y
    Expert Opin Ther Pat; 2022 May; 32(5):475-505. PubMed ID: 35062845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The path to the clinic: a comprehensive review on direct KRAS
    Kwan AK; Piazza GA; Keeton AB; Leite CA
    J Exp Clin Cancer Res; 2022 Jan; 41(1):27. PubMed ID: 35045886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The KRAS
    Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
    Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRAS
    Zhuang H; Fan J; Li M; Zhang H; Yang X; Lin L; Lu S; Wang Q; Liu Y
    Front Oncol; 2022; 12():915512. PubMed ID: 36033504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutics Targeting Mutant KRAS.
    Thein KZ; Biter AB; Hong DS
    Annu Rev Med; 2021 Jan; 72():349-364. PubMed ID: 33138715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of RAS: proven and potential vulnerabilities.
    Zuberi M; Khan I; O'Bryan JP
    Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glimmers of hope for targeting oncogenic KRAS-G12D.
    Tang D; Kang R
    Cancer Gene Ther; 2023 Mar; 30(3):391-393. PubMed ID: 36414681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the Clinical Development Candidate
    Fell JB; Fischer JP; Baer BR; Blake JF; Bouhana K; Briere DM; Brown KD; Burgess LE; Burns AC; Burkard MR; Chiang H; Chicarelli MJ; Cook AW; Gaudino JJ; Hallin J; Hanson L; Hartley DP; Hicken EJ; Hingorani GP; Hinklin RJ; Mejia MJ; Olson P; Otten JN; Rhodes SP; Rodriguez ME; Savechenkov P; Smith DJ; Sudhakar N; Sullivan FX; Tang TP; Vigers GP; Wollenberg L; Christensen JG; Marx MA
    J Med Chem; 2020 Jul; 63(13):6679-6693. PubMed ID: 32250617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PI3Kα overcomes resistance to KRas
    Qi WL; Li HY; Wang Y; Xu L; Deng JT; Zhang X; Wang YX; Meng LH
    Acta Pharmacol Sin; 2023 May; 44(5):1083-1094. PubMed ID: 36411339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Breakthrough Brought about by Targeting KRAS
    Ning W; Yang Z; Kocher GJ; Dorn P; Peng RW
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 143D, a novel selective KRAS
    Xu LS; Zheng SX; Mei LH; Yang KX; Wang YF; Zhou Q; Kong XT; Zheng MY; Jiang HL; Xie CY
    Acta Pharmacol Sin; 2023 Jul; 44(7):1475-1486. PubMed ID: 36725884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS G12C fragment screening renders new binding pockets.
    Mathieu M; Steier V; Fassy F; Delorme C; Papin D; Genet B; Duffieux F; Bertrand T; Delarbre L; Le-Borgne H; Parent A; Didier P; Marquette JP; Lowinski M; Houtmann J; Lamberton A; Debussche L; Alexey R
    Small GTPases; 2022 Jan; 13(1):225-238. PubMed ID: 34558391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.